Warning: fopen(/home/virtual/e-apem/journal/upload/ip_log_2021-12.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 73 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 74 Myhre syndrome: the first case in Korea

Myhre syndrome: the first case in Korea

Article information

Ann Pediatr Endocrinol Metab. 2021;26(3):210-214
Publication date (electronic) : 2021 May 12
doi : https://doi.org/10.6065/apem.2040214.107
1Department of Pediatrics, Inje University Ilsan Paik Hospital, Goyang, Korea
2Department of Pediatrics, Seoul National Universit y Bundang Hospital, Seongnam, Korea
Address for correspondence: Jieun Lee Department of Pediatrics, Inje University Ilsan Paik Hospital, Inje University College of Medicine, 170 Juhwa-ro, Ilsanseo-gu, Goyang 10380, Korea Email: jieunlee@paik.ac.kr
Received 2020 September 25; Revised 2020 December 6; Accepted 2021 February 1.

Abstract

Myhre syndrome (MS) is a rare autosomal-dominant disorder characterized by short stature, intellectual disability, skeletal anomalies, restricted joint mobility, distinctive facial dysmorphism, and deafness. Early diagnosis of MS is difficult because its features progress and become noticeable at school age. Recently, the SMAD4 gene was identified as the major gene responsible for MS. Herein, we report the first Korean case of MS after identification of a SMAD4 mutation by clinical exome sequencing. The patient was born small for gestational age, and she had the typical clinical features of MS, including short stature, characteristic facial appearance, developmental delay, and selective mutism. She was diagnosed with central precocious puberty. Because of the patient’s precocious puberty and short stature, we administered combined recombinant human growth hormone and gonadotropin-releasing hormone agonist treatments, which resulted in improved height. While there have been 79 cases of MS reported worldwide, to our knowledge, this is the first case of genetically-confirmed MS in Korea.

Highlights

Myhre syndrome is a rare autosomal-dominant disorder characterized by short stature, intellectual disability, skeletal anomalies, restricted joint mobility, distinctive facial dysmorphism, and deafness. We report the first Korean case of genetically-confirmed Myhre syndrome in Korea.

Introduction

Myhre syndrome (MS; OMIM 139210) is a rare autosomal-dominant disorder characterized by short stature, intellectual disability, skeletal anomalies, restricted joint mobility, distinctive facial dysmorphism, and deafness [1]. The skeletal anomalies include thickened calvarium, brachydactyly with cone-shaped epiphyses, shortened tubular bones, hypoplastic iliac wings, and large pedicles of the vertebrae [2]. Facial dysmorphism consists of maxillary hypoplasia, prognathism, short palpebral fissure, short philtrum, and small mouth. Additional multisystem involvement is reported, including in the cardiovascular (congenital heart defects, pericardial effusion, constrictive pericarditis, restrictive cardiomyopathy, and hypertension), respiratory (choanal stenosis, laryngotracheal stenosis, and restrictive pulmonary disorder), and gastrointestinal (pyloric stenosis and duodenal stricture) systems [3]. Patients with MS can develop various long-term and life-threatening complications [4]. Recently, SMAD4 was identified as the major gene responsible for MS. Most patients have missense mutations at a single codon site (Ile500) of the SMAD4 gene [1]. To date, there have been 79 reported cases worldwide [5]. In this study, we report the first Korean case of MS.

Case report

The patient was a 13-year-old female who was born to a 37-year-old female and a 38-year-old male. She was delivered vaginally at 41 weeks of gestation and weighed 2.6 kg (-1.6 standard deviation score [SDS]). She had a healthy brother, and there was no family history of short stature, mental retardation, or genetic disorders. Her father's height was 178 cm (1.2 SDS), and her mother's height was 161 cm (0.5 SDS). At the age of 5 months, she was found to have a patent ductus arteriosus (PDA) and received PDA ligation.

Her early developmental milestones were below normal limits. While attending preschool, she was found to have learning disabilities, delayed motor development, and impaired social interactions. She was nonverbal in preschool and diagnosed with selective mutism when she was 5 years old. She was referred to our neuropsychiatric department when she was 6 years old. A psychological test estimated her intelligence quotient and mental age to be 64 and 5.5 years, respectively. Her height had always remained below the third percentile.

At 8 years old, she was referred to the pediatric endocrinology clinic due to her short stature. On physical examination, her height was 115.5 cm (-2.1 SDS), and her weight was 26.0 kg (0 SDS). She had a short neck, prognathism, blepharophimosis, clinodactyly, and a shield chest (Fig. 1).

Fig. 1.

The patient demonstrated a short neck, blepharophimosis, and prognathism.

Endocrinological tests showed normal insulin-like growth factor-1 level and thyroid function. The results of chromosome analysis were normal (46,XX). No pathologic findings were identified in mutation analysis of the PTPN11 gene for Noonan syndrome. The results of brain magnetic resonance imaging were normal. Skull radiographs showed a thickened calvarium and prognathism (Fig. 2A, B), a hand radiograph showed clinodactyly and bone age appropriate for chronological age (Fig. 2C), and a whole-spine radiograph showed large vertebral pedicles and mild scoliosis (Fig. 2D, E). Clinical exome sequencing was performed and revealed a c.1498A>G (p.Ile500Val) variant in the SMAD4 gene, which was confirmed by Sanger sequencing. Further, familial genotyping (farther, mother, and younger brother) was performed by Sanger sequencing. According to the genetic test results (Fig. 3), the detected variant was confirmed as a de novo variant. Moreover, it is an additional evidence of pathogenicity according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines (PM6: De novo [assumed] in a patient with the disease and no family history) [6].

Fig. 2.

Skeletal radiographs. (A, B) Skull x-rays showing thickened calvarium and prognathism. (C) A hand x-ray showing clinodactyly. (D, E) Spinal x-rays showing mild scoliosis and large vertebral pedicles.

Fig. 3.

Sanger sequencing confirmation of the heterozygous mutation of SMAD4. Mutation of c.1498A>G (p.Ile500Val) in exon 4 of SMAD was found by clinical exome sequencing and confirmed by Sanger sequencing analysis.

Ophthalmologic examination, audiometric assessment, and laryngoscopy were performed to identify complications such as hypermetropia, farsightedness, astigmatism, strabismus, congenital cataract, hearing loss, and laryngotracheal stenosis. No complications were found.

When the patient was 8 years 11 months, her physical examination revealed a height of 117.0 cm (-2.0 SDS) and a weight of 27.1 kg (-0.4 SDS; body mass index=19.8 kg/m2, 1.0 SDS). Her breast development was Tanner stage II. A luteinizing hormone-releasing stimulation test showed a peak level of 5.8 IU/L. Her bone age was 10.5 years. These findings indicated central precocious puberty.

After receiving the diagnosis of central precocious puberty, she started gonadotropin-releasing hormone agonist (GnRHa). She simultaneously started recombinant human growth hormone (rhGH) treatment because she was born small for gestational age, and no catch-up growth had occurred. GnRHa treatment was discontinued after about 3 years, and rhGH treatment was discontinued at the age of 14 years due to her bone age of 15 years. After 4-year GnRHa and 5-year rhGH treatments, her final height improved from -2.0 SDS at 8 years 11 months (117.0 cm) to -1.6 SDS at 14 years (150.6 cm).

Discussion

MS is a rare developmental disorder affecting various systems over time [7]. Early diagnosis of MS is difficult because some of its features become apparent at school age [8]. Multifocal investigation is required to monitor potentially life-threatening complications.

MS shares some of its features with other syndromes. The differential diagnosis includes disorders like acromicric dysplasia, geleophysic dysplasia, and Weill-Marchesani syndrome. Acromicric dysplasia overlaps with MS in displaying short stature, thickened skin, and joint stiffness, but MS is distinguished by facial features, intrauterine growth restriction, mental retardation, and severity of muscular and cutaneous involvement, as well as more frequent cardiac anomalies and hearing loss [9]. Geleophysic dysplasia is a progressive disorder characterized by short stature, short hands and feet, and distinctive facial features and is associated with organomegaly, which is rare in MS [3]. Weill-Marchesani syndrome is characterized by short stature, brachydactyly, and joint stiffness, but it also features typical ocular disorders including microspherophakia, myopia, ectopia lentis, and glaucoma [10]. While SMAD4 mutations have been identified in MS, FBN1 mutations have been identified in acromicric dysplasia, ADAMTSL2, and FBN1 mutations in geleophysic dysplasia, and ADAMTS10, LTPBP2, and FBN1 mutations in Weill-Marchesani syndrome.

The patient in the present case exhibited typical features of MS, including short stature, intellectual disability, and facial dysmorphism. Identification of a SMAD4 gene mutation led to the diagnosis.

MS was first described in 1981, as a rare condition defined by a combination of the following symptoms: short stature, limited joint mobility, facial and skeletal dysmorphism, muscular hypertrophy, thick skin, variable intellectual performance, and ophthalmological and cardiovascular complications [4,11]. De novo heterozygous missense mutations in the SMAD4 gene have been identified as an underlying mechanism of the syndrome via disruption of the transforming growth factor-beta/bone morphogenetic protein (TGF-β/BMP) signaling cascade involved in embryonic development of connective tissue and the cardiovascular and central nervous systems [4,11,12]. SMADA4 is a central signaling component of the SMAD pathway that induces signals from TGF-β, a key mediator of fibrotic disease [13]. TGF-β ligands are drivers of extracellular matrix deposition, creating a concentrated pool of pro-fibrotic factors at the site of injury [14].

Typical morphological features of MS (including narrow palpebral fissures, prognathism, hypoplasia of the midface, and clinodactyly) were observed during physical examination of our patient. Radiological signs related to the syndrome were found (i.e., thick skull bones and mild scoliosis).

Although none of these were present in our patient, other symptoms commonly found in MS include ophthalmological and auditory impairments, such as cataracts, disordered retina, pseudo-papilledema, and refractory abnormalities such as hypermetropia and astigmatism, together with variably expressed hearing loss [11,15]. The majority of MS patients has delayed psychomotor development, autistic features, and variably expressed intellectual disability, all of which were present in our patient [9,16]. Missense mutations of the SMAD4 gene were among the de novo mutations in 200 genes important in neurodevelopmental disorders [17]. However, the impact of the detailed pathomechanism of mutant SMAD4 protein and TGF-β/BMP pathways on central neurological conditions is not known.

Over 70% of patients with MS have cardiovascular abnormalities, namely PDA, aortic or mitral valve stenosis, hypoplasia and/or stenosis of the abdominal aorta, pulmonary artery stenosis, pulmonary hypertension, and pericardial effusion [11,15]. Our patient had PDA and underwent PDA ligation.

Respiratory difficulties, including laryngo-tracheomalacia, bronchiolitis obliterans with organizing pneumonia, stenoses, and obstruction of both the upper and lower respiratory tracts such as that observed with hypertrophic adenoids, are common findings in MS and can lead to chronic progressive pulmonary inflammation [18]. Extrinsic interventions, such as intubation, often lead to exacerbation of existing stenoses due to defective tissue healing [19]. None of these respiratory difficulties were identified in our patient.

Sexual development problems are reported frequently in MS patients, including abnormal onset of puberty, premature menarche, and secondary amenorrhea in females and cryptorchidism and hypospadias in males [5]. While sexual development problems have been reported in many patients, little is known about the mechanism of SMAD4 variant disruption of the hypothalamic-pituitary-gonadal axis in MS cases [5]. Our patient was diagnosed with central precocious puberty at 8 years 11 months. The combined treatment of GnRHa and rhGH for children with central precocious puberty is recommended for patients with growth retardation and precocious puberty. Our patient received the combined treatment and showed improved final height.

MS is a rare genetic disorder that is caused by a SMAD4 mutation. The diagnosis should be considered when patients present with characteristic facial dysmorphism, joint contractures, brachydactyly, and short stature. Regular surveillance and anticipatory monitoring are necessary in MS because of associated life-threatening cardiovascular and respiratory manifestations [20]. Moreover, patients with MS can have a markedly abnormal fibroproliferative response to surgical intervention. Therefore, surgical intervention should be approached with extreme caution and with as little invasion as possible owing to the tendency for fibrosis development, which can cause significant morbidity and mortality.

In conclusion, we described the first Korean patient with MS, and the diagnosis was confirmed by the identification of a SMAD4 gene mutation.

Notes

Ethical statement

Written informed consent was obtained from the parents of the child for publication of this case report.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

References

1. Caputo V, Bocchinfuso G, Castori M, Traversa A, Pizzuti A, Stella L, et al. Novel SMAD4 mutation causing Myhre syndrome. Am J Med Genet A 2014;164A:1835–40.
2. Le Goff C, Michot C, Cormier-Daire V. Myhre syndrome. Clin Genet 2014;85:503–13.
3. Starr LJ, Lindor NM, Lin AE. Myhre Syndrome. In : Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al, eds. GeneReviews((R)) Seattle (WA): University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved. 1993.
4. Garavelli L, Maini I, Baccilieri F, Ivanovski I, Pollazzon M, Rosato S, et al. Natural history and life-threatening complications in Myhre syndrome and review of the literature. Eur J Pediatr 2016;175:1307–15.
5. Li H, Cheng B, Hu X, Li C, Su J, Zhang S, et al. The first two Chinese Myhre syndrome patients with the recurrent SMAD4 pathogenic variants: Functional consequences and clinical diversity. Clin Chim Acta 2020;500:128–34.
6. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.
7. Nomura R, Miyai K, Nishimura G, Kashimada K, Morio T. Myhre syndrome: age-dependent progressive phenotype. Pediatr Int 2017;59:1205–6.
8. Alagia M, Cappuccio G, Pinelli M, Torella A, BrunettiPierri R, Simonelli F, et al. A child with Myhre syndrome presenting with corectopia and tetralogy of Fallot. Am J Med Genet A 2018;176:426–30.
9. Burglen L, Heron D, Moerman A, Dieux-Coeslier A, Bourguignon JP, Bachy A, et al. Myhre syndrome: new reports, review, and differential diagnosis. J Med Genet 2003;40:546–51.
10. Evereklioglu C, Hepsen IF, Er H. Weill-Marchesani syndrome in three generations. Eye (Lond) 1999;13(Pt 6):773–7.
11. Varenyiova Z, Hrckova G, Ilencikova D, Podracka L. Myhre syndrome associated with Dunbar syndrome and urinary tract abnormalities: a case report. Front Pediatr 2020;8:72.
12. Le Goff C, Mahaut C, Abhyankar A, Le Goff W, Serre V, Afenjar A, et al. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet 2011;44:85–8.
13. Dawes LJ, Sleeman MA, Anderson IK, Reddan JR, Wormstone IM. TGFb et a/Smad4-dependent and-independent regulation of human lens epithelial cells. Invest Ophthalmol Vis Sci 2009;50:5318–27.
14. Walton KL, Johnson KE, Harrison CA. Targeting TGF-beta mediated SMAD signaling for the prevention of fibrosis Front Pharmacol. 2017;8:461.
15. Lin AE, Michot C, Cormier-Daire V, L'Ecuyer TJ, Matherne GP, Barnes BH, et al. Gain-of-function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. Am J Med Genet A 2016;170:2617–31.
16. Michot C, Le Goff C, Mahaut C, Afenjar A, Brooks AS, Campeau PM, et al. Myhre and LAPS syndromes: clinical and molecular review of 32 patients. Eur J Hum Genet 2014;22:1272–7.
17. Geisheker MR, Heymann G, Wang T, Coe BP, Turner TN, Stessman HAF, et al. Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains. Nat Neurosci 2017;20:1043–51.
18. McGowan R, Gulati R, McHenry P, Cooke A, Butler S, Keng WT, et al. Clinical features and respiratory complications in Myhre syndrome. Eur J Med Genet 2011;54:e553–9.
19. Alape D, Singh R, Folch E, Fernandez Bussy S, Agnew A, Majid A. Life-threatening multilevel airway stenosis due to Myhre syndrome. Am J Respir Crit Care Med 2020;201:731–2.
20. Yu KP, Luk HM, Chung BH, Lo IF. Myhre syndrome: a report of six Chinese patients and literature review. Clin Dysmorphol 2019;28:145–50.

Article information Continued

Fig. 1.

The patient demonstrated a short neck, blepharophimosis, and prognathism.

Fig. 2.

Skeletal radiographs. (A, B) Skull x-rays showing thickened calvarium and prognathism. (C) A hand x-ray showing clinodactyly. (D, E) Spinal x-rays showing mild scoliosis and large vertebral pedicles.

Fig. 3.

Sanger sequencing confirmation of the heterozygous mutation of SMAD4. Mutation of c.1498A>G (p.Ile500Val) in exon 4 of SMAD was found by clinical exome sequencing and confirmed by Sanger sequencing analysis.